Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07323654 · ClinicalTrials.gov registry record · Phase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
A Phase 2 study of Eosinophilic Asthma, sponsored by Kymera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
- 9
- Study locations
NCT07323654 is a Phase 2 study of Eosinophilic Asthma that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 264 participants, below the 506-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT07323654, a Phase 2 study of Eosinophilic Asthma, is actively recruiting participants, sponsored by Kymera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
- 9
- Study locations
Study Summary
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG KT-621
Study Locations (9)
Florida
- Kymera Investigative Site - Miami
- Kymera Investigative Site - Tampa
California
- Kymera Investigative Site - Upland
Georgia
- Kymera Investigative Site - East Point
Oklahoma
- Kymera Investigative Site - Edmond
Oregon
- Kymera Investigative Site - Clackamas
Pennsylvania
- Kymera Investigative Site - Pittsburgh
South Carolina
- Kymera Investigative Site - North Charleston
Tennessee
- Kymera Investigative Site - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07323654
The ClinicalTrials.gov registry entry for NCT07323654 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (48% lower). The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07323654 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07323654 about?
NCT07323654 is a clinical study titled "A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma". This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety...
What is the current status of trial NCT07323654?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2026-01-28. Estimated completion is 2027-12.
What conditions does trial NCT07323654 study?
This clinical trial studies the following conditions: Eosinophilic Asthma.
What interventions are being tested in trial NCT07323654?
The interventions under investigation include: Placebo (OTHER), KT-621 (DRUG).
Who is sponsoring clinical trial NCT07323654?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07323654 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Oklahoma, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
COMPLETED · Phase 2
-
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
RECRUITING · Phase 3
-
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.